Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free CEROW Stock Alerts

CERo Therapeutics (CEROW) Competitors

$0.0021 0.00 (0.00%)
As of 10/5/2026
Compare

CEROW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy CERo Therapeutics stock or one of its competitors? CERo Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CERo Therapeutics compare to Alvotech?

CERo Therapeutics (NASDAQ:CEROW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Alvotech had 3 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for Alvotech and 0 mentions for CERo Therapeutics. Alvotech's average media sentiment score of 0.70 beat CERo Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Summary

Alvotech beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and CERo Therapeutics (NASDAQ:CEROW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
CERo Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Apollomics Neutral
CERo Therapeutics Neutral

Summary

Apollomics beats CERo Therapeutics on 1 of the 1 factors compared between the two stocks.

How does CERo Therapeutics compare to Aravive?

CERo Therapeutics (NASDAQ:CEROW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Aravive Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

Summary

Aravive beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

How does CERo Therapeutics compare to bioAffinity Technologies?

CERo Therapeutics (NASDAQ:CEROW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.78 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CERo Therapeutics Neutral
bioAffinity Technologies Negative

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Summary

bioAffinity Technologies beats CERo Therapeutics on 2 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and CERo Therapeutics (NASDAQ:CEROW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

In the previous week, BioVie's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
BioVie Neutral
CERo Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
CERo Therapeutics N/A N/A N/A

Summary

BioVie and CERo Therapeutics tied by winning 0 of the 0 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CEROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CEROW vs. The Competition

Export
MetricCERo TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.88B$7.19B$13.38B
Dividend YieldN/A3.65%2.53%17.39%
P/E RatioN/A13.29273.9426.49
Price / SalesN/A1,239.12640.04108.72
Price / CashN/A126.5679.4153.24
Price / BookN/A16.1510.836.33
Net IncomeN/A-$22.65M$3.50B$381.96M
7 Day PerformanceN/A-4.16%-2.11%-0.41%
1 Month PerformanceN/A-12.16%-7.10%-4.85%
1 Year PerformanceN/A13.72%5.78%1.42%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEROW
CERo Therapeutics
N/A$0.00
flat		N/AN/A$0.00N/AN/A8
ALVOW
Alvotech
N/A$0.38
flat		N/A-65.7%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
+2.8%		N/A-45.0%$0.00$8.50MN/A15
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.34
+19.6%		N/A+70.4%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CEROW) was last updated on 10/7/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel